Search Results

1 - 4 of 4 items :

  • pharmacokinetics x
Clear All
Renal Changes in Cocaine Abuse and Addiction

, Day RO. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet 1997;33(5):344-400. 5. Nestler EJ. The neurobiology of cocaine addiction. Sci Pract Perspect 2005;3(1):4-10. 6. Volkow ND, Morales M. The brain on drugs: from reward to addiction. 2015;Cell 162:712–725. 7. Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci 2011;12(11):623-637. 8. Buettner M, Toennes SW, Buettner S, et al. Nephropathy in illicit drug dbusers: a

Open access
Basic Mechanisms of Action of the Antiepileptic Drugs

action, pharmacokinetics and interactions. Pharmacology Reports 2009;61;2:197-216. 23. Mantegazza M, Curia G, Biagini G, et al. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 2010;9:413-424. 24. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics 2007;4:18-61. 25. Miceli F, Soldovieri MV, Ambrosino Pet al. Early-onset epileptic encephalopathy caused by gain

Open access
The Heparanase Inhibitor (Sulodexide) Decreases Urine Glycosaminoglycan Excretion and Mitigates Functional and Histological Renal Damages in Diabetic Rats

pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide. Med Res Rev. 1998;18(1):1-20. 15. Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 1997;12(11):2295-300. 16. Skrha J, Perusicová J, Pont’uch P, Oksa A. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract. 1997

Open access
EU Paediatric Investigation Plans (Pips) Might Harm Children

References 1. Adamson PC. Improving the outcome for children with cancer: development of targeted new agents. CA Cancer J Clin. 2015;65: 212-220. 2. A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of Cobimetinib In Pediatric And Young Adult Patients With Previously Treated Solid Tumors. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004685-25 Accessed 20JAN2017. 3. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced

Open access